These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 26568428

  • 1. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M.
    Arthritis Res Ther; 2015 Nov 15; 17():325. PubMed ID: 26568428
    [Abstract] [Full Text] [Related]

  • 2. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D.
    Arthritis Res Ther; 2015 Sep 10; 17(1):245. PubMed ID: 26353833
    [Abstract] [Full Text] [Related]

  • 3. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.
    Ann Rheum Dis; 2017 Jan 10; 76(1):96-104. PubMed ID: 27165179
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO, Duncan B, Goel N, Davies OR, Dougados M.
    Rheumatology (Oxford); 2012 Dec 10; 51(12):2204-14. PubMed ID: 22923753
    [Abstract] [Full Text] [Related]

  • 5. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.
    Ann Rheum Dis; 2016 Jan 10; 75(1):75-83. PubMed ID: 26139005
    [Abstract] [Full Text] [Related]

  • 6. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R.
    Lancet; 2016 Dec 03; 388(10061):2763-2774. PubMed ID: 27863807
    [Abstract] [Full Text] [Related]

  • 7. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM, Park YE, Park W, Choe JY, Cho CS, Shim SC, Bae SC, Suh CH, Cha HS, Koh EM, Song YW, Yoo B, Lee SS, Park MC, Lee SH, Arendt C, Koetse W, Lee SK.
    Korean J Intern Med; 2018 Nov 03; 33(6):1224-1233. PubMed ID: 29294598
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T.
    Ann Rheum Dis; 2017 Aug 03; 76(8):1348-1356. PubMed ID: 28153828
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 03; 24(5):725-33. PubMed ID: 24372225
    [Abstract] [Full Text] [Related]

  • 10. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H.
    Ann Rheum Dis; 2015 May 03; 74(5):843-50. PubMed ID: 24431394
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 03; 24(5):715-24. PubMed ID: 24313916
    [Abstract] [Full Text] [Related]

  • 12. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, Davies O, Stahl HD, Alten R.
    Rheumatology (Oxford); 2012 Jul 03; 51(7):1226-34. PubMed ID: 22344576
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
    Bi L, Li Y, He L, Xu H, Jiang Z, Wang Y, Li X, Wei W, Gu J, Wang G, Zhang Z, Zhou B, Liu Y, Wu Z, Liu H, He D, Lv Z, Li Z, Zuo X, Dong L, Wu H, Zhang H, Chen H, Bao C, Zhang Z, Zhang M, Song H, Zheng Y, Jiang L, Liu X, Boehnlein M, Dunkel J, Shao J, Harris K, Li Z.
    Clin Exp Rheumatol; 2019 Jul 03; 37(2):227-234. PubMed ID: 30183595
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Jul 03; 24(4):552-60. PubMed ID: 24981319
    [Abstract] [Full Text] [Related]

  • 15. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
    Combe B, Furst DE, Keystone EC, van der Heijde D, Luijtens K, Ionescu L, Goel N, Emery P.
    Arthritis Care Res (Hoboken); 2016 Mar 03; 68(3):299-307. PubMed ID: 26238672
    [Abstract] [Full Text] [Related]

  • 16. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P, Filippucci E, Adami S, Meroni PL, Batticciotto A, Idolazzi L, De Lucia O, Talavera P, Kumke T, Grassi W.
    Adv Ther; 2018 Aug 03; 35(8):1153-1168. PubMed ID: 30043210
    [Abstract] [Full Text] [Related]

  • 17. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
    Curtis JR, Churchill M, Kivitz A, Samad A, Gauer L, Gervitz L, Koetse W, Melin J, Yazici Y.
    Arthritis Rheumatol; 2015 Dec 03; 67(12):3104-12. PubMed ID: 26316013
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S.
    Ann Rheum Dis; 2019 Aug 03; 78(8):1033-1040. PubMed ID: 31177099
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ.
    Clin Rheumatol; 2018 Dec 03; 37(12):3285-3296. PubMed ID: 30191421
    [Abstract] [Full Text] [Related]

  • 20. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, Staelens F, Koetse W, Bertin P.
    Arthritis Care Res (Hoboken); 2015 Feb 03; 67(2):151-60. PubMed ID: 25302624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.